Skip to main content


Log in

Successful treatment of refractory adult-onset Still’s disease with infliximab. A prospective, non-comparative series of four patients

  • Case Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript


In this prospective, non-comparative case series, four patients with severe and highly active adult-onset Still’s disease (AOSD), refractory to high doses of corticosteroids (which had been combined with methotrexate in three of them) and methotrexate were treated with infliximab (initial dose 3–5 mg/kg, continuing at intervals depending on the patient’s individual disease activity). Resolution of their symptoms, which was evident within few days after the first infusion, and a parallel rapid improvement of the acute inflammatory response indices were observed in all. Concomitant corticosteroid treatment was reduced after the first courses of treatment with infliximab, which was well tolerated, and complete disease remission was sustained during a 5–18-month follow-up period. Although further studies to confirm long-term efficacy and safety in larger numbers of patients are needed, we suggest that administration of infliximab with observation for objective improvement is the treatment of choice in cases of AOSD refractory to conventional treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others



Adult-onset Still’s disease


C-reactive protein


Erythrocyte sedimentation rate


Lactic dehydrogenase




Non-steroidal anti-inflammatory drugs


  1. Fautrel B, Le Moel G, Saint-Marcoux B et al. (2001) Diagnostic value of ferritin and glycosylated ferritin in adult onset Still’s disease. J Rheumatol 28:322–329

    CAS  PubMed  Google Scholar 

  2. Wouters JM, van de Putte LB (1986) Adult-onset Still’s disease; clinical and laboratory features, treatment and progress of 45 cases. Q J Med 61:1055–1065

    CAS  PubMed  Google Scholar 

  3. Sato M, Takeda A, Honzu H, Saku N, Minato N, Kano S (1993) Adult Still’s disease with Sjogren’s syndrome successfully treated with intravenous pulse methylprednisolone and oral cyclophosphamide. Intern Med 32:730–732

    CAS  PubMed  Google Scholar 

  4. Iglesias J, Sathiraju S, Marik PE (1999) Severe systemic inflammatory response syndrome with shock and ARDS resulting from Still’s disease: clinical response with high-dose pulse methylprednisolone therapy. Chest 115:1738–1740

    CAS  PubMed  Google Scholar 

  5. Kumakura S, Ishikura H, Munemasa S, Adachi T, Murakawa Y, Kobayashi S (1997) Adult onset Still’s disease associated hemophagocytosis. J Rheumatol 24:1645–1648

    Google Scholar 

  6. Beckham JC, Caldwell DS, Peterson BL et al. (1992) Disease severity in rheumatoid arthritis: relationship of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures. J Clin Immunol 12:353–361

    CAS  PubMed  Google Scholar 

  7. Mangge H, Kenzian H, Gallistl S et al. (1995) Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum 38:211–220

    CAS  PubMed  Google Scholar 

  8. Lange U, Teichmann J, Stracke H (2000) Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis. Eur J Med Res 5:507–511

    CAS  PubMed  Google Scholar 

  9. Van Deventer SJH (1997) Tumour necrosis factor and Crohn’s disease. Gut 40:443–448

    PubMed  Google Scholar 

  10. Sfikakis PP (2002) Behcet’s disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 61 [Suppl 2]:ii51–53

    Google Scholar 

  11. Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P (2000) Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 27:841–850

    CAS  PubMed  Google Scholar 

  12. Lovell DJ, Giannini EH, Reiff A et al. (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342:763–769

    CAS  PubMed  Google Scholar 

  13. Breban M, Vignon E, Claudepierre P et al. (2002) Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford) 41:1280–1285

    Google Scholar 

  14. Bell S, Kamm MA (2000) Antibodies to tumor necrosis factor alpha as treatment for Crohn’s disease. Lancet 355:858–860

    Article  CAS  PubMed  Google Scholar 

  15. Furst DE, Breedveld FC, Kalden JR et al. (2002) Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis 61 [Suppl 2]:ii2–7

  16. Hoshino T, Ohta A, Yang D et al. (1998) Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still’s disease. J Rheumatol 25:396–398

    CAS  PubMed  Google Scholar 

  17. Fujii T, Nojima T, Yasuoka H et al. (2001) Cytokine and immunogenetic profiles in Japanese patients with adult Still’s disease. Association with chronic articular disease. Rheumatology (Oxford) 40:1398–1404

    Google Scholar 

  18. Yamaguchi M, Ohta A, Tsunematsu T et al. (1992) Preliminary criteria for classification of adult Still’s disease. J Rheumatol 19:424–430

    CAS  PubMed  Google Scholar 

  19. Furst DE, Cush J, Kaufmann S, Siegel J, Kurth R (2002) Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann Rheum Dis 61[Suppl 2]:ii62–63

  20. Reference omitted

  21. Hanauer SB, Sandborn W, Practice Parameters Committee of the American College of Gastroenterology (2001) Management of Crohn’s disease in adults. Am J Gastroenterol 96:635–643

    Google Scholar 

  22. Cavagna L, Caporali R, Epis O, Bobbio-Pallavicini F, Montecucco C (2001) Infliximab in the treatment of adult Still’s disease refractory to conventional therapy. Clin Exp Rheumatol 19:329–332

    CAS  PubMed  Google Scholar 

  23. Kraetsch HG, Antoni C, Kalden JR, Manger B (2001) Successful treatment of a small cohort of patients with adult onset of Still’s disease with infliximab: first experiences. Ann Rheum Dis 60 [Suppl 3]:iii55–57

  24. Huffstutter JE, Sienknecht CW (2002) Treatment of resistant Adult Still’s disease with infliximab-A report of two cases. Arthritis Rheum 46[Suppl]:326

  25. Caramaschi P, Biasi D, Carletto A, Bambara LM (2002) A case of adult onset Still’s disease treated with infliximab. Clin Exp Rheumatol 20:113

    CAS  PubMed  Google Scholar 

  26. Husni ME, Maier AL, Mease PJ et al. (2002) Etanercept in the treatment of adult patients with Still’s disease. Arthritis Rheum 46:1171–1176

    Article  CAS  PubMed  Google Scholar 

  27. Van Deventer SJH (2001) Transmembrane TNF-a, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn’s disease. Gastroenterology 121:1242–1246

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Alexander Kokkinos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kokkinos, A., Iliopoulos, A., Greka, P. et al. Successful treatment of refractory adult-onset Still’s disease with infliximab. A prospective, non-comparative series of four patients. Clin Rheumatol 23, 45–49 (2004).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: